Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15;8(6):1778-1790.
doi: 10.1021/acsptsci.5c00209. eCollection 2025 Jun 13.

Structural Insights into the Substrate Egress Pathways Explains Specificity and Inhibition of Human Glucose Transporters (GLUT1 and GLUT9)

Affiliations

Structural Insights into the Substrate Egress Pathways Explains Specificity and Inhibition of Human Glucose Transporters (GLUT1 and GLUT9)

Manming Xu et al. ACS Pharmacol Transl Sci. .

Abstract

Glucose transporters (GLUTs) play critical roles in cellular energy homeostasis and substrate-specific transport. Dysfunctional mutations can cause GLUT1 deficiency syndrome, and excessive expression of GLUT1 is linked to cancer progression, while abnormal regulation of urate transport by GLUT9 is associated with hyperuricemia and gout. In this study, machine-learning-driven molecular dynamics simulations have been employed to investigate the mechanistic insights into the substrate egress pathways of GLUT1 and GLUT9, including the inhibition mechanism of GLUT9 by apigenin. Our findings reveal that intracellular helices play a crucial role in facilitating the transition from inward-closed to -open conformations in both transporters. Additionally, aromatic residues, F291 and W388 in GLUT1 and W336 and F435 in GLUT9, are identified as key mediators of conformational changes. Analysis of substrate exit pathways provides mechanistic insights into transport profiles and aligns with clinically observed mutations. Furthermore, the inhibitory effect of apigenin on GLUT9 is shown to arise from steric hindrance due to increased substrate size rather than stable interactions. These findings enhance our understanding of GLUT transporter dynamics and highlight the potential of targeting substrate pathways for therapeutic intervention.

Keywords: GLUT1; GLUT9; apigenin; glucose; pathways; urate.

PubMed Disclaimer

Similar articles

References

    1. Mueckler M., Thorens B.. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 2013;34(2–3):121–138. doi: 10.1016/j.mam.2012.07.001. - DOI - PMC - PubMed
    1. Thorens B., Mueckler M.. Glucose transporters in the 21st Century. Am. J. Physiol.: Endocrinol. Metab. 2010;298(2):E141–E145. doi: 10.1152/ajpendo.00712.2009. - DOI - PMC - PubMed
    1. Bibert S., Hess S. K., Firsov D., Thorens B., Geering K., Horisberger J. D., Bonny O.. Mouse GLUT9: evidences for a urate uniporter. Am. J. Physiol. Renal Physiol. 2009;297(3):F612–F619. doi: 10.1152/ajprenal.00139.2009. - DOI - PubMed
    1. Dehghan A., Kottgen A., Yang Q., Hwang S. J., Kao W. L., Rivadeneira F., Boerwinkle E., Levy D., Hofman A., Astor B. C.. et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–1961. doi: 10.1016/S0140-6736(08)61343-4. - DOI - PMC - PubMed
    1. Shen Z., Xu L., Wu T., Wang H., Wang Q., Ge X., Kong F., Huang G., Pan X.. Structural basis for urate recognition and apigenin inhibition of human GLUT9. Nat. Commun. 2024;15(1):5039. doi: 10.1038/s41467-024-49420-9. - DOI - PMC - PubMed

LinkOut - more resources